Clinical Trials Logo

Clinical Trial Summary

This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion


Clinical Trial Description

This single ascending dose study will evaluate the safety, tolerability, and PK of single doses of galidesivir vs. placebo administered as IV infusions in healthy subjects enrolled in up to four dose cohorts of 8 subjects each. A single dose of study drug will be administered per cohort: 6 subjects will receive galidesivir IV, and 2 subjects will receive matching placebo. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03800173
Study type Interventional
Source BioCryst Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date December 10, 2018
Completion date April 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT03475056 - cAd3-Marburg Vaccine in Healthy Adults Phase 1
Active, not recruiting NCT05817422 - Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults Phase 2
Completed NCT04723602 - Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults Phase 1
Completed NCT00605514 - Ebola and Marburg Virus Vaccines Phase 1
Recruiting NCT06265012 - Study to Evaluate the Recombinant Vesicular Stomatitis Virus (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects Phase 1
Completed NCT00997607 - Evaluating an Ebola and a Marburg Vaccine in Uganda Phase 1